MedDataX Logo

Quadratus Lumborum Block for Total Hip Arthroplasty

NCT ID: NCT05247255

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-29

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

quadratus lumborum nerve block, analgesia, total hip arthroplasty, postoperative outcomes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

Quadratus lumborum nerve block with 0.25% ropivacaine

Group Type ACTIVE_COMPARATOR

Active Comparator

Intervention Type DRUG

QL block with 0.25% ropivacaine

Control Group

Quadratus lumborum nerve block with saline

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

QL block with saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active Comparator

QL block with 0.25% ropivacaine

Intervention Type DRUG

Placebo Comparator

QL block with saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects undergoing elective primary total hip arthroplasty

Exclusion Criteria

* patients age \< 18,
* documented allergy to local anesthetic
* presence of peripheral neuropathy
* patients with current long term opioid use defined as receiving an opioid on most days in a 90 day period
* patients with a contraindication to spinal and regional anesthesia such as coagulopathy or infection at the site of the regional technique.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Los Angeles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pamela Chia

HS Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pamela Chia, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA Medical Center, Santa Monica

Santa Monica, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jennifer Scovotti, MA

Role: CONTACT

Phone: 310-206-4484

Email: [email protected]

Pamela Chia, MD

Role: CONTACT

Phone: 310-267-83217

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pamela Chia, MD

Role: primary

Jennifer Scovotti, MA

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-001850

Identifier Type: -

Identifier Source: org_study_id